The global newborn screening market is crucial in ensuring the early detection of genetic and metabolic disorders in newborns, leading to improved health outcomes and the prevention of disabilities. It enables timely intervention and treatment, reducing disease progression and complications. Furthermore, newborn screening provides valuable information for family planning and genetic counseling, empowering families to make informed decisions. With its public health impact, the market contributes to cost reduction, improved quality of life, and the prevention of long-term disabilities. The expansion of screening to include rare diseases enhances outcomes for infants.
Access Full Report at https://www.databridgemarketresearch.com/reports/global-newborn-screening-market
Data Bridge Market Research analyses that the Newborn Screening Market is valued at USD 0.9 billion in 2021 and is expected to reach USD 1.76 billion by 2029, registering a CAGR of 8.8% during the forecast period of 2022-2029. The increasing incidence of genetic and metabolic disorders among newborns is a major driver of the global newborn screening market. Early detection and intervention through newborn screening programs can significantly improve the outcomes and quality of life for affected infants.
Key Findings of the Study
Growing awareness is expected to drive the market's growth rate
Growing awareness and education about newborn screening have played a vital role in market growth. Educational campaigns conducted by healthcare organizations and advocacy groups have helped disseminate information about the potential benefits of newborn screening, such as timely diagnosis of genetic and metabolic disorders, leading to early treatment and improved outcomes for infants. This increased awareness has driven the demand for newborn screening services and propelled the market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Test Type (Dried Blood Spot Test, Hearing Screen Test, Critical Congenital Heart Diseases (CCHD) Test), Product Type (Instruments, Reagents, Assay Kits), Technology (Tandem Mass Spectrometry, Hearing Screen Technology, Pulse Oximetry Screening Technology, Immunoassays and Enzymatic Assays, Electrophoresis, DNA-Based Assays), Disease Type (Critical Congenital Heart Diseases, Newborn Hearing Loss, Sickle Cell Disease, Phenylketonuria (PKU), Cystic Fibrosis (CF), Maple Syrup Urine Disease, Others), End User (Hospital, Paediatric Clinics, Clinics)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
PerkinElmer Inc., (U.S.), Demant A/S (Denmark), Natus Medical Incorporated (U.S), Bio-Rad Laboratories (U.S.), Luminex Corporation (US), F. Hoffmann-La Roche Ltd., (Switzerland), Thermo Fisher Scientific Inc., (U.S.), Bruker (U.S.), Danaher (U.S.), Medtronic (Ireland), Chromsystems Instruments & Chemicals GmbH (Germany), Trivitron Healthcare (India), Baebies Inc., (U.S.), and RECIPE Chemicals + Instruments GmbH (Germany) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The newborn screening market is segmented on the basis of test type, product type, technology, disease type, and end user.
- On the basis of test type, the newborn screening market is segmented into dried blood spot test, hearing screen test, and critical congenital heart diseases (CCHD) test. Hearing screen test dominates in the test type segment in the global newborn screening market due to their critical role in the early detection of hearing impairments, enabling early intervention and treatment for infants, leading to improved communication and developmental outcomes with a CAGR of 11.4% in the forecast period of 2022 to 2029.
- On the basis of product type, the newborn screening market is segmented into instruments, reagents, and assay kits. The instruments segment will dominate the product type segment of the global newborn screening market with a CAGR of 11.0% in the forecast period 2022 to 2029 due to various specialized equipment and devices used for sample collection, testing, and analysis. These instruments play a crucial role in ensuring accurate and efficient screening processes, contributing to the segment's dominance.
In 2022, the instruments segment will dominate the product type segment of the global newborn screening market
In 2022, the instruments segment will dominate the product type segment of the global newborn screening market owing to a variety of specialized tools and instruments used to collect, test, and analyze samples. These tools are essential for ensuring accurate and effective screening procedures, which helps explain the segment's dominance with a CAGR of 11.0% in the forecast period 2022 to 2029.
- On the basis of technology, the newborn screening market is segmented into tandem mass spectrometry, hearing screen technology, pulse oximetry screening technology, immunoassays and enzymatic assays, electrophoresis, and DNA-based assays. Hearing screen technology in newborn screening dominates the technology segment of the market due to its non-invasive nature, accuracy in detecting hearing impairments, and ability to identify potential hearing issues at an early stage, allowing for timely intervention and improved long-term outcomes for infants with a CAGR of 10.7% in the forecast period of 2022 to 2029.
- On the basis of disease type, the newborn screening market is segmented into critical congenital heart diseases, newborn hearing loss, sickle cell disease, phenylketonuria (PKU), cystic fibrosis (CF), maple syrup urine disease, and others. The critical congenital heart disease segment is expected to dominate the disease type segment of the global newborn screening market with a CAGR of 11.0% in the forecast period 2022 to 2029 due to the increasing recognition of the importance of early detection of heart conditions in infants. Screening for CCHD helps identify newborns at risk and enables timely interventions, leading to improved outcomes and reduced morbidity and mortality
In 2022, the critical congenital heart diseases segment is expected to dominate the disease type segment of the global newborn screening market
In 2022, the critical congenital heart diseases segment is expected to dominate the disease type segment of the global newborn screening market owing to the growing understanding of the significance of infant heart conditions being discovered early. The identification of newborns who may be at risk for CCHD through screening enables prompt interventions, which improve outcomes and lower morbidity and mortality with a CAGR of 11.0% in the forecast period 2022 to 2029.
- On the basis of end user, the newborn screening market is bifurcated into hospital, paediatric clinics, and clinics. The hospital segment is expected to dominate the end user segment of the global newborn screening market with 71.27% market share in the forecast period 2022 to2029 due to the primary healthcare settings where newborns receive initial screening tests. Hospitals have the necessary infrastructure, healthcare professionals, and resources to conduct newborn screening efficiently and provide follow-up care as required.
Major Players
Data Bridge Market Research recognizes the following companies as the major newborn screening market players in newborn screening market are Bruker (U.S.), Danaher (U.S.), Medtronic (Ireland), Chromsystems Instruments & Chemicals GmbH (Germany), Trivitron Healthcare (India), Baebies Inc., (U.S.), and RECIPE Chemicals + Instruments GmbH (Germany)
Market Development
- In 2022, Trivitron Healthcare launched a Centre of Excellence (CoE) with state-of-the-art research and development and manufacturing facilities at AMTZ Campus, Vishakhapatnam, India, for metabolomics, genomics, newborn screening, and molecular diagnostics.
- In 2022, Rady Children’s Institute for Genomic Medicine launched a program to advance and evaluate the scalability of a diagnostic and precision medicine guidance tool called BeginNGS (pronounced “beginnings”) to screen newborns for approximately 400 genetic diseases that have known treatment options using rapid whole genome sequencing.
- In 2020, For the EONIS screening assay used to check newborns for SMA (spinal muscular atrophy), SCID (severe combined immunodeficiency), and XLA (X-linked agammaglobulinemia), PerkinElmer (US) received CE-IVD approval.
- In 2019, The GSP Neonatal Creatine Kinase MM (CK-MM) kit from PerkinElmer (US) has been approved by the US FDA for use in screening newborns for Duchenne muscular dystrophy (DMD).
- In 2019, The easyScreen BERAphone, a hearing screening tool, was introduced by Demant A/S (Denmark) at the 64th International Congress of Hearing Aid Acousticians in Nuremberg, Germany.
Regional Analysis
Geographically, the countries covered in the newborn screening market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in newborn screening market during the forecast period 2022-2029
North America's dominance in the newborn screening market can be attributed to several factors. The region is home to several major players in the healthcare industry who offer advanced screening technologies and comprehensive newborn screening solutions. Additionally, North America has well-established newborn screening programs supported by government initiatives and favorable reimbursement policies. These factors contribute to the widespread adoption of newborn screening, ensuring early detection and intervention for newborns at risk of genetic and metabolic disorders in the region.
Asia-Pacific is estimated to be the fastest-growing region in the newborn screening market in the forecast period 2022-2029
Asia-Pacific is poised to experience substantial growth in the newborn screening market. The region's increasing screening rate, driven by improved healthcare infrastructure and awareness programs, plays a crucial role in the early detection and diagnosis of genetic and metabolic disorders in newborns. Growing awareness about the benefits of early diagnosis among healthcare professionals and caregivers further contributes to the market's expansion. The rising emphasis on preventive healthcare and the implementation of government initiatives for newborn screening propel the market growth in Asia-Pacific.
For more detailed information about the newborn screening market report, click here – https://www.databridgemarketresearch.com/reports/global-newborn-screening-market
